For generations, ADHD has been understood as a single condition wearing different masks — inattentive, hyperactive, or both — but new neuroimaging research suggests the disorder is not one thing at all. Scientists have identified three distinct subtypes, each with its own biological signature in the brain, including one that appears markedly more severe than the others. This discovery invites medicine to reconsider not just how ADHD is treated, but what it fundamentally is — a question with profound consequences for the millions who live inside its diagnosis.
Brain Scans Reveal Three Distinct ADHD Subtypes, Including Severe Form
Related Coverage
Massive wildfires across central and western Indonesia have scorched forests and peatland, generating thick smoke that b…
Google News · Aug 25 Starbucks Brings Back Pumpkin Spice Latte With Six New Fall DrinksStarbucks launches its annual Pumpkin Spice Latte alongside six new fall drinks, marking the start of the seasonal bever…
The Guardian · Aug 25 Matcha boom doubles in Australia as $8 green lattes become café stapleMatcha orders in Australia have doubled year-on-year, with under-35s driving demand for the $8 green beverage now consid…
The Guardian · Aug 25 Europe's summer heatwaves claim at least 35,000 excess deaths, toll expected to riseAt least 35,000 excess deaths occurred across Europe during four record-breaking summer heatwaves, with the true toll li…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
Medical research on ADHD brain subtypes has no geopolitical implications; this is a domestic healthcare/scientific matter.
Economic Lens
Brain imaging research identifying three ADHD subtypes, including a severe form, has limited direct economic impact but may drive future healthcare spending and pharmaceutical development.
Consumers may face increased diagnostic costs if brain imaging becomes standard ADHD screening. Long-term benefits include more targeted treatments, potentially reducing overall healthcare costs and improving productivity through better-matched interventions.
Potential regulatory updates to ADHD diagnostic criteria; possible insurance coverage expansions for advanced neuroimaging; education policy adjustments for identified severe subtypes; pharmaceutical companies may pursue targeted drug development for specific subtypes.